Tofacitinib and steroid taper for PMR
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study tests whether a daily pill (tofacitinib) combined with a short course of steroids can help people with active PMR use less steroids over time. You must have high disease activity and not have taken steroids or biologics in the past two weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with polymyalgia rheumatica (PMR).
- You have not taken steroids or biologic drugs for PMR in the last 2 weeks.
- You are between 50 and 88 years old and weigh between 99 and 187 pounds.
- Your blood tests show high inflammation (ESR over 20 or CRP over 5).
- You do not have other major conditions like giant cell arteritis, rheumatoid arthritis, active infections, or certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This trial tests combining two oral medications, iguratimod and tofacitinib (Xeljanz), to see if they work better together for rheumatoid arthritis that is not well controlled on current treatment.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
Hear when a new Polymyalgia Rheumatica trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.